$395 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 104 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ISHARES TRcall | $13,485,000 | – | 100,000 | +100.0% | 3.41% | – | |
| New | TEVA PHARMACEUTICAL INDS LTDcall | $7,794,000 | – | 215,000 | +100.0% | 1.97% | – | |
| New | TEVA PHARMACEUTICAL FIN LLCdbcv 0.250% 2/0 | $4,247,000 | – | 6,585 | +100.0% | 1.08% | – | |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $3,728,000 | – | 45,000 | +100.0% | 0.94% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $3,315,000 | – | 45,000 | +100.0% | 0.84% | – |
| SLB | New | SCHLUMBERGER LTD | $2,885,000 | – | 34,361 | +100.0% | 0.73% | – |
| New | ISHARES TRput | $2,682,000 | – | 12,000 | +100.0% | 0.68% | – | |
| XLRN | New | ACCELERON PHARMA INC | $2,552,000 | – | 100,000 | +100.0% | 0.65% | – |
| GNMX | New | AEVI GENOMIC MEDICINE INC | $2,331,000 | – | 450,000 | +100.0% | 0.59% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $2,244,000 | – | 100,000 | +100.0% | 0.57% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $1,806,000 | – | 125,000 | +100.0% | 0.46% | – |
| PTCT | New | PTC THERAPEUTICS INC | $1,637,000 | – | 150,000 | +100.0% | 0.41% | – |
| PCRX | New | PACIRA PHARMACEUTICALS INC | $1,615,000 | – | 50,000 | +100.0% | 0.41% | – |
| TSEM | New | TOWER SEMICONDUCTOR LTD | $1,597,000 | – | 83,940 | +100.0% | 0.40% | – |
| CTSH | New | COGNIZANT TECHNOLOGY SOLUTIOcl a | $1,562,000 | – | 27,875 | +100.0% | 0.40% | – |
| FB | New | FACEBOOK INCcl a | $1,503,000 | – | 13,062 | +100.0% | 0.38% | – |
| BA | New | BOEING CO | $1,306,000 | – | 8,392 | +100.0% | 0.33% | – |
| AXGT | New | AXOVANT SCIENCES LTD | $1,242,000 | – | 100,000 | +100.0% | 0.31% | – |
| MA | New | MASTERCARD INCORPORATEDcl a | $1,118,000 | – | 10,825 | +100.0% | 0.28% | – |
| PRQR | New | PROQR THRAPEUTICS N V | $980,000 | – | 200,000 | +100.0% | 0.25% | – |
| RARX | New | RA PHARMACEUTICALS INC | $911,000 | – | 60,000 | +100.0% | 0.23% | – |
| TMO | New | THERMO FISHER SCIENTIFIC INC | $898,000 | – | 6,363 | +100.0% | 0.23% | – |
| LJPC | New | LA JOLLA PHARMACEUTICAL CO | $888,000 | – | 50,677 | +100.0% | 0.22% | – |
| TBT | New | PROSHARES TR | $761,000 | – | 18,650 | +100.0% | 0.19% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $453,000 | – | 125,000 | +100.0% | 0.12% | – |
| SEDG | New | SOLAREDGE TECHNOLOGIES INC | $325,000 | – | 26,203 | +100.0% | 0.08% | – |
| New | HORIZON PHARMA PLCcall | $293,000 | – | 18,100 | +100.0% | 0.07% | – | |
| SEE | New | SEALED AIR CORP NEW | $159,000 | – | 3,500 | +100.0% | 0.04% | – |
| RXDX | New | IGNYTA INC | $117,000 | – | 22,065 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 39 | Q2 2024 | 8.4% |
| MERCK & CO INC NEW | 38 | Q2 2024 | 8.4% |
| NICE Systems Ltd | 30 | Q2 2024 | 4.4% |
| BIOGEN INC | 29 | Q2 2024 | 6.7% |
| PFIZER INC | 28 | Q2 2024 | 9.2% |
| SAREPTA THERAPEUTICS INC | 28 | Q2 2024 | 3.2% |
| JOHNSON & JOHNSON | 27 | Q2 2024 | 8.0% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| SYNDAX PHARMACEUTICALS INC | 25 | Q2 2024 | 3.9% |
| ASTRAZENECA PLC | 24 | Q2 2024 | 7.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Skye Bioscience, Inc. | February 08, 2024 | 1,301,518 | 5.4% |
| Inozyme Pharma, Inc. | February 05, 2024 | 1,562,907 | 2.5% |
| Jasper Therapeutics, Inc. | February 05, 2024 | 7,130,625 | 6.4% |
| Praxis Precision Medicines, Inc. | February 05, 2024 | 328,986 | 3.7% |
| ProMIS Neurosciences Inc. | February 05, 2024 | 1,892,474 | 10.0% |
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-11-04 |
| N-PX | 2024-08-29 |
| SC 13G | 2024-08-20 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.